Success Metrics

Clinical Success Rate

33.3%

Based on 1 completed trials

Completion Rate

33%(1/3)

Active Trials

2(40%)

Results Posted

0%(0 trials)

Terminated

2(40%)

Phase Distribution

Ph phase_1

20%

Ph phase_2

80%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

1(20.0%)

Phase 2Efficacy & side effects

4(80.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(1)

Terminated(2)

Detailed Status

Active, not recruiting2

Terminated2

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

33.3%

Most Advanced

Phase 2

Trials by Phase

Phase 11 (20.0%)

Phase 24 (80.0%)

Trials by Status

completed120%

active_not_recruiting240%

terminated240%

Recent Activity

2 active trials

Showing 5 of 5

active_not_recruitingphase_2

Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)

NCT06427668

completedphase_1

Study of SPG302 in Healthy Volunteers and ALS Participants

NCT05882695

Clinical Trials (5)

Showing 5 of 5 trials

NCT06442462Phase 2

Study of SPG302 in Adults With Schizophrenia

Active Not Recruiting

NCT06833281Phase 2

Extension Study of Participants From SPG302-ALZ-101

Terminated

NCT06903286Phase 2

Extension Study of Participants From SPG302-ALS-001

Terminated

NCT06427668Phase 2

Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)

Active Not Recruiting

NCT05882695Phase 1

Study of SPG302 in Healthy Volunteers and ALS Participants

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5